"Shock waves" from GSK's $750M settlement on alleged cGMP failures, lawyers say

GlaxoSmithKline's recent agreement to pay $750 million to resolve civil and criminal liability in connection with alleged cGMP failures at its now-shuttered facility in Cidra, Puerto Rico, is outside the norm and some believe opens up a new frontier for US whistleblower suits.